CS
INO icon

Credit Suisse’s Inovio Pharmaceuticals INO Stock Holding History

Credit Suisse’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,938
Closed -$18K – 2982
2023
Q4 		$18K Hold
2,938
– – ﹤0.01% 3047
2023
Q3 		$13.7K Sell
2,938
-1,812
-38% -$10K ﹤0.01% 3128
2023
Q2 		$25.5K Sell
4,750
-25,627
-84% -$207K ﹤0.01% 3153
2023
Q1 		$299K Buy
30,377
+4,971
+20% +$84.7K ﹤0.01% 2996
2022
Q4 		$476K Buy
25,406
+6,421
+34% +$146K ﹤0.01% 2816
2022
Q3 		$393K Buy
18,985
+309
+2% +$7.91K ﹤0.01% 2936
2022
Q2 		$388K Sell
18,676
-9,399
-33% -$265K ﹤0.01% 3003
2022
Q1 		$1.21M Buy
28,075
+463
+2% +$20.9K ﹤0.01% 2422
2021
Q4 		$1.65M Buy
27,612
+1,016
+4% +$81.4K ﹤0.01% 2936
2021
Q3 		$2.28M Sell
26,596
-17,466
-40% -$1.75M ﹤0.01% 2726
2021
Q2 		$4.9M Buy
44,062
+8,696
+25% +$835K ﹤0.01% 2097
2021
Q1 		$3.94M Sell
35,366
-2,883
-8% -$379K ﹤0.01% 2274
2020
Q4 		$4.06M Buy
38,249
+13,762
+56% +$1.83M ﹤0.01% 2273
2020
Q3 		$3.41M Sell
24,487
-1,470
-6% -$307K ﹤0.01% 2036
2020
Q2 		$8.39M Buy
25,957
+22,300
+610% +$3.58M 0.01% 1395
2020
Q1 		$327K Sell
3,657
-258
-7% -$15.9K ﹤0.01% 3375
2019
Q4 		$156K Sell
3,915
-3,138
-44% -$94.4K ﹤0.01% 4028
2019
Q3 		$174K Buy
7,053
+1,877
+36% +$57.1K ﹤0.01% 3892
2019
Q2 		$182K Buy
5,176
+210
+4% +$8.34K ﹤0.01% 3864
2019
Q1 		$223K Buy
4,966
+998
+25% +$50.3K ﹤0.01% 3729
2018
Q4 		$190K Sell
3,968
-2,913
-42% -$177K ﹤0.01% 3681
2018
Q3 		$459K Buy
6,881
+748
+12% +$41.7K ﹤0.01% 3349
2018
Q2 		$288K Sell
6,133
-1,915
-24% -$106K ﹤0.01% 3639
2018
Q1 		$455K Buy
8,048
+1,272
+19% +$68.8K ﹤0.01% 3405
2017
Q4 		$337K Sell
6,776
-1,537
-18% -$95.3K ﹤0.01% 3587
2017
Q3 		$632K Buy
8,313
+2,971
+56% +$221K ﹤0.01% 3407
2017
Q2 		$502K Sell
5,342
-5,715
-52% -$489K ﹤0.01% 3153
2017
Q1 		$879K Buy
11,057
+5,755
+109% +$459K ﹤0.01% 2961
2016
Q4 		$442K Sell
5,302
-1,525
-22% -$138K ﹤0.01% 3505
2016
Q3 		$763K Sell
6,827
-2,368
-26% -$262K ﹤0.01% 3166
2016
Q2 		$1.02M Buy
9,195
+8
+0.1% +$972 ﹤0.01% 2907
2016
Q1 		$960K Buy
9,187
+3,835
+72% +$296K ﹤0.01% 2756
2015
Q4 		$432K Sell
5,352
-8,704
-62% -$693K ﹤0.01% 3487
2015
Q3 		$974K Buy
14,056
+1,722
+14% +$150K ﹤0.01% 2845
2015
Q2 		$1.21M Buy
12,334
+8,484
+220% +$906K ﹤0.01% 2993
2015
Q1 		$377K Sell
3,850
-6,049
-61% -$586K ﹤0.01% 3728
2014
Q4 		$1.09M Buy
9,899
+1,548
+19% +$189K ﹤0.01% 3065
2014
Q3 		$988K Buy
8,351
+1,037
+14% +$129K ﹤0.01% 3055
2014
Q2 		$949K Sell
7,314
-339
-4% -$40K ﹤0.01% 3332
2014
Q1 		$1.22M Buy
7,653
+6,018
+368% +$864K ﹤0.01% 2949
2013
Q4 		$227K Buy
+1,635
New +$164K ﹤0.01% 4265

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Credit Suisse's INO Position: Q1 2024 in Review

Credit Suisse sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 2,938 shares — an estimated $18K sold.

Credit Suisse first reported a position in INO in Q4 2013 and held it in 41 quarters. The position peaked at $8.39M in Q2 2020. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Credit Suisse reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Credit Suisse sold 2,938 Inovio Pharmaceuticals shares in Q1 2024, an estimated $18K.
  • Credit Suisse first reported a position in Inovio Pharmaceuticals in Q4 2013 and held it in 41 quarters.
  • Credit Suisse's Inovio Pharmaceuticals position peaked at $8.39M in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.